Modification of myocardial substrate utilisation: a new therapeutic paradigm in cardiovascular disease

Roger M. Beadle, Michael Frenneaux

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Therapies that aim to modify cardiac substrate utilisation are designed to increase metabolic efficiency. Although the main energy supply for the heart is generally provided by the oxidation of fatty acids, the heart is a metabolic omnivore and able to consume glucose as well as lactate and amino acids in varying proportions. A shift from fatty acid oxidation to glucose oxidation leads to lower oxygen consumption per unit of ATP produced. This concept of reduced oxygen utilisation underlies the use of metabolic modulating agents to treat chronic stable angina. Furthermore, the model of an energy-starved heart now forms the basis for our understanding of both ischaemic and non-ischaemic heart failure. Potential alterations in substrate utilisation and thus myocardial efficiency underlie the use of metabolic agents in heart failure. This is achieved by either promoting glucose or reducing the utilisation of fatty acids. Such a shift results in a relatively greater production of ATP per unit of oxygen consumed. With an ongoing demand for treatment options in ischaemic heart disease and a growing epidemic of heart failure, new treatment modalities beyond contemporary therapy need consideration.

Original languageEnglish
Pages (from-to)824-830
Number of pages7
JournalHeart
Volume96
Issue number11
DOIs
Publication statusPublished - Jun 2010

Keywords

  • congestive-heart-failure
  • fatty-acid oxidation
  • left-ventricular function
  • low-flow ischemia
  • idiopathic dilated cardiomyopathy
  • insulin-potassium infusion
  • glucose-transporter GLUT4
  • coronary-artery-disease
  • perhexiline-maleate
  • metabolic modulation

Cite this

Modification of myocardial substrate utilisation : a new therapeutic paradigm in cardiovascular disease. / Beadle, Roger M.; Frenneaux, Michael.

In: Heart, Vol. 96, No. 11, 06.2010, p. 824-830.

Research output: Contribution to journalArticle

Beadle, Roger M. ; Frenneaux, Michael. / Modification of myocardial substrate utilisation : a new therapeutic paradigm in cardiovascular disease. In: Heart. 2010 ; Vol. 96, No. 11. pp. 824-830.
@article{35cd7f7c532b4389a5b83b69c9f99f36,
title = "Modification of myocardial substrate utilisation: a new therapeutic paradigm in cardiovascular disease",
abstract = "Therapies that aim to modify cardiac substrate utilisation are designed to increase metabolic efficiency. Although the main energy supply for the heart is generally provided by the oxidation of fatty acids, the heart is a metabolic omnivore and able to consume glucose as well as lactate and amino acids in varying proportions. A shift from fatty acid oxidation to glucose oxidation leads to lower oxygen consumption per unit of ATP produced. This concept of reduced oxygen utilisation underlies the use of metabolic modulating agents to treat chronic stable angina. Furthermore, the model of an energy-starved heart now forms the basis for our understanding of both ischaemic and non-ischaemic heart failure. Potential alterations in substrate utilisation and thus myocardial efficiency underlie the use of metabolic agents in heart failure. This is achieved by either promoting glucose or reducing the utilisation of fatty acids. Such a shift results in a relatively greater production of ATP per unit of oxygen consumed. With an ongoing demand for treatment options in ischaemic heart disease and a growing epidemic of heart failure, new treatment modalities beyond contemporary therapy need consideration.",
keywords = "congestive-heart-failure, fatty-acid oxidation, left-ventricular function, low-flow ischemia, idiopathic dilated cardiomyopathy, insulin-potassium infusion, glucose-transporter GLUT4, coronary-artery-disease, perhexiline-maleate, metabolic modulation",
author = "Beadle, {Roger M.} and Michael Frenneaux",
year = "2010",
month = "6",
doi = "10.1136/hrt.2009.190256",
language = "English",
volume = "96",
pages = "824--830",
journal = "Heart",
issn = "1355-6037",
publisher = "BMJ Publishing Group",
number = "11",

}

TY - JOUR

T1 - Modification of myocardial substrate utilisation

T2 - a new therapeutic paradigm in cardiovascular disease

AU - Beadle, Roger M.

AU - Frenneaux, Michael

PY - 2010/6

Y1 - 2010/6

N2 - Therapies that aim to modify cardiac substrate utilisation are designed to increase metabolic efficiency. Although the main energy supply for the heart is generally provided by the oxidation of fatty acids, the heart is a metabolic omnivore and able to consume glucose as well as lactate and amino acids in varying proportions. A shift from fatty acid oxidation to glucose oxidation leads to lower oxygen consumption per unit of ATP produced. This concept of reduced oxygen utilisation underlies the use of metabolic modulating agents to treat chronic stable angina. Furthermore, the model of an energy-starved heart now forms the basis for our understanding of both ischaemic and non-ischaemic heart failure. Potential alterations in substrate utilisation and thus myocardial efficiency underlie the use of metabolic agents in heart failure. This is achieved by either promoting glucose or reducing the utilisation of fatty acids. Such a shift results in a relatively greater production of ATP per unit of oxygen consumed. With an ongoing demand for treatment options in ischaemic heart disease and a growing epidemic of heart failure, new treatment modalities beyond contemporary therapy need consideration.

AB - Therapies that aim to modify cardiac substrate utilisation are designed to increase metabolic efficiency. Although the main energy supply for the heart is generally provided by the oxidation of fatty acids, the heart is a metabolic omnivore and able to consume glucose as well as lactate and amino acids in varying proportions. A shift from fatty acid oxidation to glucose oxidation leads to lower oxygen consumption per unit of ATP produced. This concept of reduced oxygen utilisation underlies the use of metabolic modulating agents to treat chronic stable angina. Furthermore, the model of an energy-starved heart now forms the basis for our understanding of both ischaemic and non-ischaemic heart failure. Potential alterations in substrate utilisation and thus myocardial efficiency underlie the use of metabolic agents in heart failure. This is achieved by either promoting glucose or reducing the utilisation of fatty acids. Such a shift results in a relatively greater production of ATP per unit of oxygen consumed. With an ongoing demand for treatment options in ischaemic heart disease and a growing epidemic of heart failure, new treatment modalities beyond contemporary therapy need consideration.

KW - congestive-heart-failure

KW - fatty-acid oxidation

KW - left-ventricular function

KW - low-flow ischemia

KW - idiopathic dilated cardiomyopathy

KW - insulin-potassium infusion

KW - glucose-transporter GLUT4

KW - coronary-artery-disease

KW - perhexiline-maleate

KW - metabolic modulation

U2 - 10.1136/hrt.2009.190256

DO - 10.1136/hrt.2009.190256

M3 - Article

VL - 96

SP - 824

EP - 830

JO - Heart

JF - Heart

SN - 1355-6037

IS - 11

ER -